2119583-24-1: Nilotinib Ethylimidazole Analog

2119583-24-1: Nilotinib Ethylimidazole Analog

Nilotinib Ethylimidazole Analog (CAS No: 2119583-24-1) is an impurity present in Nilotinib which is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia in the chronic phase and accelerated phase who are resistant to or intolerant of prior imatinib therapy.

Additional information on CAS 2119583-24-1

Catalogue No.

VE008151
CAS No.

2119583-24-1
Molecular Formula

C29H24F3N7O
Molecular Weight

543.54 g/mol
Parent drug

Nilotinib
IUPAC Name

N-(3-(4-Ethyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
Synonyms

N/A
References

Kondra, S. B., et al. “A Validated Stability-Indicative UPLC Method for Nilotinib Hydrochloride for the Determination of Process-Related and Degradation Impurities.” Journal of Chromatographic Science, vol. 52, no. 8, Sept. 2013, pp. 880–85, https://doi.org/10.1093/chromsci/bmt134.?Hughes, Timothy, et al. “Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase.” Journal of Clinical Oncology, vol. 27, no. 25, Sept. 2009, pp. 4204–10
Status

In-stock

Other products related to nilotinib

[rfq_list]

Login first to add product to RFQ List

Request a quote

2119583-24-1: Nilotinib Ethylimidazole Analog

2119583-24-1: Nilotinib Ethylimidazole Analog
Catalogue No.

VE008151
CAS No.

2119583-24-1
Molecular Formula

C29H24F3N7O
Molecular Weight

543.54 g/mol
Parent drug

Nilotinib
IUPAC Name

N-(3-(4-Ethyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
Synonyms

N/A
References

Kondra, S. B., et al. “A Validated Stability-Indicative UPLC Method for Nilotinib Hydrochloride for the Determination of Process-Related and Degradation Impurities.” Journal of Chromatographic Science, vol. 52, no. 8, Sept. 2013, pp. 880–85, https://doi.org/10.1093/chromsci/bmt134.?Hughes, Timothy, et al. “Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase.” Journal of Clinical Oncology, vol. 27, no. 25, Sept. 2009, pp. 4204–10
Status

In-stock
ListName

Nilotinib Ethylimidazole Analog
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden